Prescribing advice
Glucagon-like peptide-1 (GLP-1) analogues act as GLP-1 receptor agonists.
A National Patient Safety Alert (NatPSA) on the shortage of GLP-1 receptor agonists has been issued.
Prescribing advice is available from the following key resources listed in the NatPSA:
- Type 2 diabetes in adults: management (NICE guideline [NG28])
- Joint PCDS and ABCD guidance: GLP-1 receptor agonist national shortage
Dulaglutide
Limited availability
The following dulaglutide products will be in limited supply and are unable to support uplift in demand from other GLP-1 receptor agonists:
- Trulicity 0.75 mg solution for injection in pre-filled pen
- Trulicity 1.5 mg solution for injection in pre-filled pen
- Trulicity 3 mg solution for injection in pre-filled pen
- Trulicity 4.5 mg solution for injection in pre-filled pen
Affected
The following active supply issues exist:
Exenatide
Available
The following exenatide products are available but are unable to support uplift in demand from other GLP-1 receptor agonists:
- Byetta 5micrograms/0.02mL solution for injection 1.2mL pre-filled pens
- Byetta 10micrograms/0.04mL solution for injection 1.2mL pre-filled pens
- Bydureon 2mg/0.85mL prolonged-release suspension for injection 1.2mL pre-filled pens
Liraglutide
Limited availability
The following injectable liraglutide products will be in limited supply and are unable to support uplift in demand from other GLP-1 receptor agonists:
- Victoza 6mg/mL solution for injection in prefilled pen
- Saxenda 6mg/mL solution for injection in prefilled pen
Affected
The following active supply issues exist:
- Shortage of Liraglutide (Victoza) 6mg/ml solution for injection
- Shortage of Liraglutide (Saxenda) 6mg/ml solution for injection 3ml pre-filled disposable devices
Semaglutide injection
Limited availability
The following injectable semaglutide products will be in limited supply and are unable to support uplift in demand from other GLP-1 receptor agonists:
- Ozempic 0.25mg solution for injection in pre-filled pen
- Ozempic 0.5mg solution for injection in pre-filled pen
- Ozempic 1mg solution for injection in pre-filled pen
Available
Wegovy (semaglutide) is now available in the following presentations by Novo Nordisk:
- Wegovy 0.25mg FlexTouch solution for injection in pre-filled pen
- Wegovy 0.5mg FlexTouch solution for injection in pre-filled pen
- Wegovy 1mg FlexTouch solution for injection in pre-filled pen
- Wegovy 1.7mg FlexTouch solution for injection in pre-filled pen
- Wegovy 2.4mg FlexTouch solution for injection in pre-filled pen
Accessing Wegovy for weight loss: Everything you need to know contains further information regarding access on the NHS.
Affected
The following active supply issues exist:
Semaglutide tablets
Limited availability
The following oral semaglutide products will be in limited supply and are unable to support uplift in demand from other GLP-1 receptor agonists:
- Rybelsus 3mg tablets
- Rybelsus 7mg tablets
- Rybelsus 14mg tablets
Affected
The following active supply issues exist:
Further advice
Prescribing available insulins
Medicines Supply Tool
Update history
- Product details and link to further information added for Wegovy. Status changed from intermittent to limited availability for other GLP-1 RAs.
- Content updated to reflect the publication of the NatPSA and Saxenda supply issue added.
- Bydureon has been added to the exenatide section.
- Published